Literature DB >> 21486393

Acute generalised exanthematous pustulosis following intravitreal Ranibizumab.

David C Bosanquet1, Wendy L Davies, Kenneth May, Keith G Harding, Girish K Patel.   

Abstract

Acute generalised exanthematous pustulosis, or AGEP, is a well documented cutaneous drug reaction. It typically occurs within 48 hours of oral antibiotics, but can be caused by other medications and, occasionally, after viral infections. We present a case of AGEP following intravitreal injection of Ranibizumab, a monoclonal antibody vascular endothelial growth factor inhibitor.
© 2011 The Authors. © 2011 Blackwell Publishing Ltd and Medicalhelplines.com Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21486393      PMCID： PMC7950962          DOI： 10.1111/j.1742-481X.2011.00799.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN： 1742-4801            Impact factor:   3.315


  6 in total

1.  A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis.

Authors:  Jacob Mashiah; Sarah Brenner
Journal:  Arch Dermatol       Date:  2003-09

2.  Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.

Authors:  Michaela Schwarz; Karl-Anton Kreuzer; Gökben Baskaynak; Bernd Dörken; Philipp le Coutre
Journal:  Eur J Haematol       Date:  2002-10       Impact factor: 2.997

3.  Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Jeffrey S Heier; Gary Hantsbarger; Naveed Shams
Journal:  Ophthalmology       Date:  2006-04       Impact factor: 12.079

4.  Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.

Authors:  Laurence Legros; Christine Bourcier; Arnaud Jacquel; François-Xavier Mahon; Jill-Patrice Cassuto; Patrick Auberger; Gilles Pagès
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

5.  Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).

Authors:  A Sidoroff; A Dunant; C Viboud; S Halevy; J N Bouwes Bavinck; L Naldi; M Mockenhaupt; J-P Fagot; J-C Roujeau
Journal:  Br J Dermatol       Date:  2007-09-13       Impact factor: 9.302

Review 6.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640
  6 in total
  3 in total

1.  Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report.

Authors:  Norihiro Nagai; Mari Ibuki; Hajime Shinoda; Kaori Kameyama; Kazuo Tsubota; Yoko Ozawa
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 2.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

Review 3.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.